KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Asset Writedowns and Impairment: 2012-2024

Historic Asset Writedowns and Impairment for TherapeuticsMD (TXMD) over the last 9 years, with Dec 2024 value amounting to $7,000.

  • TherapeuticsMD's Asset Writedowns and Impairment was N/A to $7,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $608,000, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is N/A change from last year.
  • Latest data reveals that TherapeuticsMD reported Asset Writedowns and Impairment of $7,000 as of Q4 2024, which was down 88.14% from $59,000 recorded in Q1 2023.
  • Over the past 5 years, TherapeuticsMD's Asset Writedowns and Impairment peaked at $500,000 during Q4 2020, and registered a low of -$122,621 during Q1 2020.
  • In the last 3 years, TherapeuticsMD's Asset Writedowns and Impairment had a median value of $163,500 in 2022 and averaged $152,000.
  • As far as peak fluctuations go, TherapeuticsMD's Asset Writedowns and Impairment crashed by 249.02% in 2020, and later surged by 462.08% in 2021.
  • Over the past 5 years, TherapeuticsMD's Asset Writedowns and Impairment (Quarterly) stood at $500,000 in 2020, then plummeted by 101.40% to -$7,000 in 2021, then rose by 24.65% to $268,000 in 2022, then tumbled by 78.47% to $59,000 in 2023, then reached $7,000 in 2024.
  • Its Asset Writedowns and Impairment was $7,000 in Q4 2024, compared to $59,000 in Q1 2023 and $268,000 in Q2 2022.